Annex 1, Interpreted: What PIC/S Inspectors Will Actually Expect

On this episode of The Regulatory Mix, we break down the new PIC/S Recommendation PI 058-1, Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022).

The document entered into force on October 28, 2026 and was developed jointly through the PIC/S, EMA, and WHO Annex 1 implementation group. Importantly, PI 058-1 does not create new GMP requirements. Instead, it provides a harmonized Q&A interpretation of how inspectors are expected to apply the revised Annex 1 during sterile manufacturing inspections.

The episode focuses on the practical issues sterile manufacturers are most likely to feel during inspection: how the Contamination Control Strategy should function as a living system rather than a standalone document, expectations for PUPSIT, the limitations of VHP as a sterilization method, airflow visualization and first-air protection, WFI monitoring, APS frequency and failure response, personnel qualification, single-use systems, and environmental monitoring.

One of the most important themes is that Annex 1 compliance is increasingly about demonstrating how controls work together. A firm may have strong procedures for gowning, environmental monitoring, disinfection, utilities, APS, and equipment qualification, but inspectors will expect those controls to be connected through the CCS and supported by actual performance data.

The document also provides useful clarification in areas that have generated debate since the revised Annex 1 became effective, including cleanroom transfer practices, alternative airflow velocities, disinfectant rotation, cold WFI systems, supplier reliance for single-use systems, and what happens after a failed APS.

The takeaway: PI 058-1 gives industry a much clearer view of how Annex 1 will be interpreted at the inspection level. For sterile manufacturers, this is a good document to use for a targeted gap assessment before the inspector arrives.

PIC/S PI 058-1: https://picscheme.org/docview/11495

PIC/S Announcement: https://picscheme.org/en/news/150/adoption-and-entry-into-force-of-pics-recommendation-pi-058

Disclosure: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.